| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 22 | 2025 | 129 | 3.490 |
Why?
|
| Anti-Bacterial Agents | 26 | 2025 | 207 | 2.590 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 12 | 2023 | 55 | 2.120 |
Why?
|
| Intraabdominal Infections | 9 | 2025 | 10 | 1.940 |
Why?
|
| Candidiasis | 3 | 2025 | 13 | 1.700 |
Why?
|
| Skin | 11 | 2025 | 73 | 1.670 |
Why?
|
| Klebsiella pneumoniae | 10 | 2021 | 38 | 1.630 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 11 | 2025 | 40 | 1.630 |
Why?
|
| beta-Lactamases | 13 | 2025 | 42 | 1.610 |
Why?
|
| Bacterial Proteins | 13 | 2025 | 48 | 1.580 |
Why?
|
| Vancomycin Resistance | 8 | 2014 | 16 | 1.560 |
Why?
|
| Intensive Care Units | 10 | 2024 | 119 | 1.550 |
Why?
|
| Chlorhexidine | 10 | 2024 | 29 | 1.550 |
Why?
|
| Humans | 93 | 2025 | 12210 | 1.510 |
Why?
|
| Gram-Positive Bacterial Infections | 10 | 2014 | 26 | 1.470 |
Why?
|
| Staphylococcal Infections | 13 | 2023 | 81 | 1.400 |
Why?
|
| Anti-Infective Agents, Local | 9 | 2024 | 26 | 1.280 |
Why?
|
| Enterococcus | 10 | 2014 | 24 | 1.230 |
Why?
|
| Klebsiella Infections | 9 | 2020 | 35 | 1.140 |
Why?
|
| Antimicrobial Stewardship | 5 | 2025 | 11 | 1.060 |
Why?
|
| Female | 46 | 2025 | 6967 | 0.970 |
Why?
|
| Infection Control | 12 | 2024 | 76 | 0.950 |
Why?
|
| Candida | 3 | 2023 | 9 | 0.900 |
Why?
|
| Carrier State | 10 | 2024 | 29 | 0.880 |
Why?
|
| Baths | 6 | 2024 | 19 | 0.860 |
Why?
|
| Drug Resistance, Bacterial | 5 | 2022 | 26 | 0.860 |
Why?
|
| Bacteremia | 12 | 2019 | 53 | 0.810 |
Why?
|
| Middle Aged | 27 | 2025 | 4040 | 0.740 |
Why?
|
| Male | 35 | 2025 | 6810 | 0.740 |
Why?
|
| Genomics | 6 | 2025 | 26 | 0.730 |
Why?
|
| Medical Order Entry Systems | 4 | 2025 | 8 | 0.710 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2025 | 2 | 0.710 |
Why?
|
| Mupirocin | 4 | 2019 | 8 | 0.700 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2019 | 73 | 0.700 |
Why?
|
| Chicago | 13 | 2025 | 453 | 0.690 |
Why?
|
| Disease Outbreaks | 8 | 2023 | 38 | 0.690 |
Why?
|
| Dermatomycoses | 1 | 2021 | 4 | 0.680 |
Why?
|
| Adult | 25 | 2025 | 3550 | 0.670 |
Why?
|
| Enterobacteriaceae | 3 | 2019 | 16 | 0.650 |
Why?
|
| Nursing Homes | 5 | 2025 | 27 | 0.630 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 3 | 2010 | 6 | 0.570 |
Why?
|
| Genome, Bacterial | 2 | 2017 | 7 | 0.560 |
Why?
|
| Microbial Sensitivity Tests | 11 | 2021 | 39 | 0.560 |
Why?
|
| Aged | 20 | 2025 | 3999 | 0.560 |
Why?
|
| Pregnancy Complications, Infectious | 7 | 2024 | 15 | 0.530 |
Why?
|
| Urinary Tract Infections | 3 | 2024 | 19 | 0.500 |
Why?
|
| Mass Screening | 3 | 2014 | 86 | 0.480 |
Why?
|
| United States | 13 | 2024 | 989 | 0.460 |
Why?
|
| Skin Care | 3 | 2024 | 10 | 0.460 |
Why?
|
| Enterobacteriaceae Infections | 4 | 2021 | 20 | 0.450 |
Why?
|
| Health Facilities | 3 | 2024 | 12 | 0.450 |
Why?
|
| Long-Term Care | 4 | 2025 | 24 | 0.440 |
Why?
|
| Enterococcus faecium | 3 | 2008 | 6 | 0.430 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2014 | 5 | 0.430 |
Why?
|
| Virulence Factors | 1 | 2014 | 5 | 0.430 |
Why?
|
| Bacterial Toxins | 1 | 2014 | 3 | 0.430 |
Why?
|
| Child | 10 | 2024 | 614 | 0.430 |
Why?
|
| Bacteriological Techniques | 1 | 2014 | 5 | 0.410 |
Why?
|
| Culture Media | 1 | 2014 | 8 | 0.410 |
Why?
|
| Anal Canal | 1 | 2014 | 3 | 0.410 |
Why?
|
| Pregnancy | 8 | 2024 | 193 | 0.410 |
Why?
|
| Respiratory Tract Infections | 3 | 2025 | 12 | 0.400 |
Why?
|
| Bacterial Load | 2 | 2012 | 10 | 0.390 |
Why?
|
| Clostridium Infections | 2 | 2023 | 19 | 0.390 |
Why?
|
| Communicable Diseases | 2 | 2023 | 7 | 0.370 |
Why?
|
| Gram-Positive Bacteria | 1 | 2012 | 7 | 0.370 |
Why?
|
| Escherichia coli Infections | 3 | 2014 | 13 | 0.370 |
Why?
|
| Bacterial Infections | 2 | 2024 | 26 | 0.370 |
Why?
|
| Hospitals | 8 | 2025 | 68 | 0.360 |
Why?
|
| Hand | 3 | 2008 | 24 | 0.360 |
Why?
|
| Methicillin Resistance | 3 | 2007 | 10 | 0.360 |
Why?
|
| Escherichia coli | 2 | 2010 | 18 | 0.340 |
Why?
|
| Feces | 2 | 2024 | 40 | 0.340 |
Why?
|
| Gloves, Protective | 2 | 2008 | 4 | 0.330 |
Why?
|
| Phylogeny | 4 | 2025 | 35 | 0.330 |
Why?
|
| Staphylococcus aureus | 3 | 2019 | 36 | 0.330 |
Why?
|
| Rectum | 4 | 2024 | 21 | 0.320 |
Why?
|
| beta-Lactams | 1 | 2010 | 3 | 0.310 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 3 | 2014 | 11 | 0.310 |
Why?
|
| Soft Tissue Infections | 3 | 2025 | 21 | 0.300 |
Why?
|
| Minisatellite Repeats | 1 | 2008 | 6 | 0.270 |
Why?
|
| Endemic Diseases | 1 | 2008 | 5 | 0.270 |
Why?
|
| Community-Acquired Infections | 4 | 2019 | 25 | 0.270 |
Why?
|
| Diagnostic Imaging | 5 | 2024 | 43 | 0.260 |
Why?
|
| Hospitalization | 7 | 2025 | 158 | 0.260 |
Why?
|
| Vancomycin-Resistant Enterococci | 2 | 2024 | 9 | 0.250 |
Why?
|
| Genes, Bacterial | 2 | 2016 | 4 | 0.250 |
Why?
|
| Health Personnel | 2 | 2023 | 36 | 0.250 |
Why?
|
| Sequence Analysis, DNA | 4 | 2017 | 33 | 0.250 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2024 | 28 | 0.250 |
Why?
|
| Epidemiological Monitoring | 2 | 2024 | 10 | 0.240 |
Why?
|
| Sensitivity and Specificity | 5 | 2014 | 252 | 0.240 |
Why?
|
| Reimbursement, Incentive | 2 | 2024 | 3 | 0.230 |
Why?
|
| Whole Genome Sequencing | 1 | 2025 | 1 | 0.230 |
Why?
|
| Genome, Fungal | 1 | 2025 | 1 | 0.230 |
Why?
|
| Daptomycin | 1 | 2005 | 6 | 0.230 |
Why?
|
| Anti-Infective Agents | 2 | 2023 | 14 | 0.230 |
Why?
|
| Air Microbiology | 1 | 2025 | 2 | 0.220 |
Why?
|
| Environmental Monitoring | 1 | 2025 | 3 | 0.220 |
Why?
|
| Aged, 80 and over | 8 | 2025 | 2152 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 3 | 2016 | 57 | 0.220 |
Why?
|
| Blood Culture | 1 | 2024 | 1 | 0.220 |
Why?
|
| Cholangitis | 1 | 2024 | 1 | 0.220 |
Why?
|
| Cholecystitis, Acute | 1 | 2024 | 2 | 0.220 |
Why?
|
| Abdominal Abscess | 1 | 2024 | 3 | 0.220 |
Why?
|
| Diverticulitis | 1 | 2024 | 5 | 0.210 |
Why?
|
| Appendicitis | 1 | 2024 | 11 | 0.210 |
Why?
|
| Universal Precautions | 2 | 2024 | 6 | 0.210 |
Why?
|
| Specimen Handling | 3 | 2023 | 21 | 0.210 |
Why?
|
| Time Factors | 5 | 2017 | 695 | 0.210 |
Why?
|
| Patient Discharge | 1 | 2024 | 77 | 0.210 |
Why?
|
| Pneumonia | 1 | 2024 | 33 | 0.200 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 2 | 2021 | 7 | 0.200 |
Why?
|
| Risk Factors | 7 | 2021 | 1049 | 0.190 |
Why?
|
| Molecular Epidemiology | 5 | 2021 | 16 | 0.190 |
Why?
|
| Pandemics | 2 | 2020 | 126 | 0.190 |
Why?
|
| Drug Resistance, Microbial | 6 | 2023 | 29 | 0.190 |
Why?
|
| Hand Disinfection | 3 | 2010 | 8 | 0.180 |
Why?
|
| Bacteria | 2 | 2025 | 33 | 0.180 |
Why?
|
| Vancomycin | 3 | 1999 | 18 | 0.180 |
Why?
|
| Disinfection | 2 | 2019 | 4 | 0.180 |
Why?
|
| Subacute Care | 1 | 2021 | 4 | 0.180 |
Why?
|
| Disease Transmission, Infectious | 2 | 2019 | 14 | 0.170 |
Why?
|
| Universities | 1 | 2021 | 20 | 0.170 |
Why?
|
| Students | 1 | 2021 | 19 | 0.170 |
Why?
|
| Mandatory Programs | 1 | 2021 | 2 | 0.170 |
Why?
|
| Federal Government | 1 | 2021 | 3 | 0.170 |
Why?
|
| State Government | 1 | 2021 | 3 | 0.170 |
Why?
|
| Local Government | 1 | 2021 | 3 | 0.170 |
Why?
|
| Disease Reservoirs | 3 | 2010 | 8 | 0.170 |
Why?
|
| Masks | 1 | 2021 | 4 | 0.170 |
Why?
|
| Viruses | 1 | 2020 | 2 | 0.170 |
Why?
|
| Gammaproteobacteria | 1 | 2021 | 3 | 0.170 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 8 | 0.160 |
Why?
|
| Plasmids | 2 | 2019 | 28 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 45 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 48 | 0.150 |
Why?
|
| Fluoroquinolones | 1 | 2019 | 10 | 0.150 |
Why?
|
| Delivery of Health Care | 3 | 2024 | 62 | 0.150 |
Why?
|
| Population Surveillance | 3 | 2015 | 46 | 0.150 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2020 | 6 | 0.140 |
Why?
|
| Conjugation, Genetic | 2 | 1997 | 3 | 0.140 |
Why?
|
| Models, Biological | 2 | 2014 | 191 | 0.130 |
Why?
|
| Nasal Cavity | 2 | 2014 | 12 | 0.130 |
Why?
|
| Personnel, Hospital | 2 | 2008 | 9 | 0.130 |
Why?
|
| Glycopeptides | 1 | 1997 | 2 | 0.130 |
Why?
|
| DNA, Bacterial | 4 | 2019 | 22 | 0.130 |
Why?
|
| Administration, Intranasal | 3 | 2024 | 10 | 0.130 |
Why?
|
| Selection, Genetic | 1 | 2016 | 2 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2016 | 27 | 0.120 |
Why?
|
| Melioidosis | 1 | 2015 | 3 | 0.120 |
Why?
|
| Burkholderia pseudomallei | 1 | 2015 | 3 | 0.120 |
Why?
|
| Gram-Negative Bacteria | 2 | 2013 | 12 | 0.110 |
Why?
|
| Travel | 1 | 2015 | 11 | 0.110 |
Why?
|
| Ofloxacin | 1 | 1995 | 1 | 0.110 |
Why?
|
| Levofloxacin | 1 | 1995 | 4 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2012 | 827 | 0.110 |
Why?
|
| Case-Control Studies | 5 | 2021 | 256 | 0.110 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2015 | 2 | 0.110 |
Why?
|
| Water Microbiology | 1 | 2015 | 3 | 0.110 |
Why?
|
| Hospitals, University | 1 | 2015 | 12 | 0.110 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2015 | 5 | 0.110 |
Why?
|
| Critical Illness | 1 | 2015 | 52 | 0.110 |
Why?
|
| Cost Savings | 1 | 2014 | 15 | 0.110 |
Why?
|
| Pharynx | 1 | 2014 | 8 | 0.110 |
Why?
|
| Acute Disease | 2 | 2024 | 90 | 0.100 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 8 | 0.100 |
Why?
|
| Mandatory Reporting | 1 | 2013 | 1 | 0.100 |
Why?
|
| Infant, Newborn | 4 | 2021 | 312 | 0.100 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2013 | 1 | 0.100 |
Why?
|
| Infant | 3 | 2021 | 277 | 0.100 |
Why?
|
| Colorimetry | 1 | 2013 | 1 | 0.100 |
Why?
|
| Chromogenic Compounds | 1 | 2013 | 2 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 66 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2013 | 40 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2024 | 295 | 0.100 |
Why?
|
| Equipment Contamination | 1 | 2012 | 5 | 0.090 |
Why?
|
| Drug Resistance, Multiple | 1 | 2012 | 7 | 0.090 |
Why?
|
| Public Health | 2 | 2024 | 22 | 0.090 |
Why?
|
| Catheter-Related Infections | 1 | 2012 | 16 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2012 | 60 | 0.090 |
Why?
|
| California | 2 | 2024 | 27 | 0.090 |
Why?
|
| Adolescent | 5 | 2021 | 987 | 0.090 |
Why?
|
| Bacterial Typing Techniques | 2 | 2011 | 6 | 0.090 |
Why?
|
| Hospital Administration | 2 | 2014 | 13 | 0.090 |
Why?
|
| Serratia marcescens | 1 | 2010 | 3 | 0.080 |
Why?
|
| Serratia Infections | 1 | 2010 | 3 | 0.080 |
Why?
|
| Staphylococcal Skin Infections | 2 | 2007 | 6 | 0.080 |
Why?
|
| Prevalence | 3 | 2019 | 174 | 0.080 |
Why?
|
| Enterococcus faecalis | 2 | 2002 | 4 | 0.080 |
Why?
|
| Length of Stay | 2 | 2024 | 126 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2021 | 320 | 0.070 |
Why?
|
| Environment | 1 | 2008 | 19 | 0.070 |
Why?
|
| Catheterization | 1 | 2007 | 23 | 0.070 |
Why?
|
| Multilocus Sequence Typing | 2 | 2021 | 8 | 0.070 |
Why?
|
| Public Housing | 1 | 2007 | 2 | 0.060 |
Why?
|
| Prisons | 1 | 2007 | 5 | 0.060 |
Why?
|
| Young Adult | 2 | 2021 | 862 | 0.060 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 6 | 0.060 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2007 | 4 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2023 | 1467 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2007 | 11 | 0.060 |
Why?
|
| DNA, Viral | 1 | 2007 | 23 | 0.060 |
Why?
|
| Viral Load | 1 | 2007 | 41 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2007 | 30 | 0.060 |
Why?
|
| Hepatitis | 1 | 2006 | 2 | 0.060 |
Why?
|
| Simplexvirus | 1 | 2006 | 2 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2007 | 55 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 1 | 2006 | 10 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 51 | 0.060 |
Why?
|
| Osteomyelitis | 1 | 2005 | 8 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2005 | 58 | 0.060 |
Why?
|
| Lumbosacral Region | 1 | 2005 | 28 | 0.060 |
Why?
|
| Genome, Viral | 1 | 2025 | 8 | 0.060 |
Why?
|
| Metagenomics | 1 | 2025 | 3 | 0.060 |
Why?
|
| Microbiota | 1 | 2025 | 34 | 0.050 |
Why?
|
| Ascomycota | 1 | 2004 | 2 | 0.050 |
Why?
|
| Mitosporic Fungi | 1 | 2004 | 2 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2024 | 3 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2024 | 7 | 0.050 |
Why?
|
| Fungemia | 1 | 2004 | 6 | 0.050 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2004 | 8 | 0.050 |
Why?
|
| Iodophors | 1 | 2024 | 3 | 0.050 |
Why?
|
| Mycoses | 1 | 2004 | 14 | 0.050 |
Why?
|
| Patient Transfer | 1 | 2024 | 11 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2004 | 37 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 161 | 0.050 |
Why?
|
| Benchmarking | 1 | 2024 | 13 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2023 | 10 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2024 | 78 | 0.050 |
Why?
|
| Illinois | 2 | 2015 | 110 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2023 | 31 | 0.050 |
Why?
|
| Respiratory System | 1 | 2023 | 5 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2023 | 5 | 0.050 |
Why?
|
| Animals | 3 | 2020 | 2083 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2023 | 22 | 0.050 |
Why?
|
| Lumbar Vertebrae | 1 | 2005 | 182 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 423 | 0.050 |
Why?
|
| Gelatinases | 1 | 2002 | 2 | 0.050 |
Why?
|
| Hemolysin Proteins | 1 | 2002 | 2 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2002 | 817 | 0.050 |
Why?
|
| Travel-Related Illness | 1 | 2021 | 2 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2018 | 1477 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 47 | 0.040 |
Why?
|
| Genotype | 1 | 2021 | 169 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 546 | 0.040 |
Why?
|
| Ecosystem | 1 | 2021 | 13 | 0.040 |
Why?
|
| Mathematics | 1 | 2000 | 25 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 4 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 12 | 0.040 |
Why?
|
| Blood-Borne Pathogens | 1 | 2020 | 3 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 38 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 79 | 0.040 |
Why?
|
| Carbapenems | 1 | 2019 | 11 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 26 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 78 | 0.040 |
Why?
|
| Hygiene | 1 | 2019 | 6 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 337 | 0.040 |
Why?
|
| Surgical Wound Infection | 1 | 1999 | 38 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 64 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 209 | 0.030 |
Why?
|
| Genitalia, Female | 1 | 1997 | 8 | 0.030 |
Why?
|
| Critical Care | 1 | 2018 | 49 | 0.030 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 1997 | 2 | 0.030 |
Why?
|
| Chromosomes, Bacterial | 1 | 1997 | 2 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 13 | 0.030 |
Why?
|
| Temperature | 1 | 2017 | 33 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 651 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 19 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 125 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 726 | 0.030 |
Why?
|
| Ceftazidime | 1 | 1996 | 6 | 0.030 |
Why?
|
| Cephalosporins | 1 | 1996 | 6 | 0.030 |
Why?
|
| HIV-1 | 1 | 1997 | 132 | 0.030 |
Why?
|
| Bacteriuria | 1 | 2015 | 2 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 23 | 0.030 |
Why?
|
| Mexico | 1 | 2015 | 7 | 0.030 |
Why?
|
| Ampicillin | 1 | 1995 | 4 | 0.030 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2015 | 8 | 0.030 |
Why?
|
| Ciprofloxacin | 1 | 1995 | 7 | 0.030 |
Why?
|
| Penicillins | 1 | 1995 | 5 | 0.030 |
Why?
|
| Gastric Juice | 1 | 2015 | 2 | 0.030 |
Why?
|
| Drinking Water | 1 | 2015 | 2 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2015 | 9 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2015 | 5 | 0.030 |
Why?
|
| Sputum | 1 | 2015 | 8 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 229 | 0.030 |
Why?
|
| HIV Infections | 1 | 1997 | 238 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2014 | 18 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2015 | 101 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2014 | 29 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2014 | 33 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2014 | 10 | 0.030 |
Why?
|
| Campylobacter Infections | 1 | 2014 | 2 | 0.030 |
Why?
|
| Diffusion | 1 | 2014 | 17 | 0.030 |
Why?
|
| Chickens | 1 | 2014 | 19 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 28 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2014 | 39 | 0.030 |
Why?
|
| Focus Groups | 1 | 2014 | 50 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2014 | 56 | 0.030 |
Why?
|
| Longevity | 1 | 2014 | 15 | 0.030 |
Why?
|
| Phenotype | 1 | 2014 | 156 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2007 | 141 | 0.020 |
Why?
|
| Contact Tracing | 1 | 2011 | 3 | 0.020 |
Why?
|
| Indiana | 1 | 2011 | 8 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 400 | 0.020 |
Why?
|
| Serratia | 1 | 2010 | 3 | 0.020 |
Why?
|
| Syringes | 1 | 2010 | 3 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 66 | 0.020 |
Why?
|
| Bedding and Linens | 1 | 2007 | 5 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2007 | 12 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2007 | 24 | 0.020 |
Why?
|
| Hospitals, Public | 1 | 2007 | 8 | 0.020 |
Why?
|
| Methicillin | 1 | 2007 | 2 | 0.020 |
Why?
|
| Soaps | 1 | 2007 | 3 | 0.020 |
Why?
|
| Alcohols | 1 | 2007 | 4 | 0.020 |
Why?
|
| Gram-Positive Cocci | 1 | 2007 | 4 | 0.020 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2007 | 8 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 2007 | 20 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 324 | 0.010 |
Why?
|
| Incidence | 1 | 2007 | 338 | 0.010 |
Why?
|
| Asphyxia Neonatorum | 1 | 1984 | 1 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1984 | 29 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1984 | 53 | 0.010 |
Why?
|
| Virulence | 1 | 2002 | 4 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2002 | 20 | 0.010 |
Why?
|
| Mortality | 1 | 2002 | 37 | 0.010 |
Why?
|
| APACHE | 1 | 2001 | 12 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2001 | 51 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1999 | 17 | 0.010 |
Why?
|
| Heating | 1 | 1997 | 3 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 1997 | 6 | 0.010 |
Why?
|
| Virus Latency | 1 | 1997 | 6 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 1997 | 10 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1997 | 12 | 0.010 |
Why?
|
| HIV Long Terminal Repeat | 1 | 1997 | 11 | 0.010 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1997 | 6 | 0.010 |
Why?
|
| Therapeutic Irrigation | 1 | 1997 | 27 | 0.010 |
Why?
|
| Monocytes | 1 | 1997 | 21 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 52 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1997 | 48 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1997 | 36 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1997 | 95 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1997 | 267 | 0.010 |
Why?
|
| Pyruvates | 1 | 1984 | 1 | 0.000 |
Why?
|
| Lactates | 1 | 1984 | 2 | 0.000 |
Why?
|
| Catecholamines | 1 | 1984 | 5 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1984 | 15 | 0.000 |
Why?
|
| Glycogen | 1 | 1984 | 10 | 0.000 |
Why?
|
| Glucagon | 1 | 1984 | 4 | 0.000 |
Why?
|
| Insulin | 1 | 1984 | 41 | 0.000 |
Why?
|
| Liver | 1 | 1984 | 57 | 0.000 |
Why?
|
| Rats | 1 | 1984 | 406 | 0.000 |
Why?
|